Iguratimod is a novel DMARD for the treatment of RA [1, 5, 22–35], which suppresses tumor necrosis factor-alpha-induced production of interleukin (IL)-6, IL‐8, and monocyte chemoattractant protein 1 via inhibition of nuclear factor kappa B activation in cultured human synovial cells and human acute monocytic leukemia cells, which indirectly inhibits damage to osteoblasts [16, 34, 36, 37]. The gene discussed is CCL2; the disease is acute monocytic leukemia.